Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Peptides and Muscle Building Marek Wawrzyk

BPC-157 TB-500 – faster regeneration after injury

BPC-157 and TB-500 are sometimes mentioned in the same breath as a pair of regenerative peptides.

BPC-157 TB-500 - faster regeneration after injury

BPC-157 and TB-500 are sometimes mentioned in the same breath as a pair of regenerative peptides. They share a research context, but differ in three areas that are rarely discussed: a different mechanism, a different anti-doping category and – in the case of TB-500 – a chemical identity different from what most descriptions claim. This article clarifies both issues, describes the state of the evidence, and clearly separates observations from animal models from what is known in humans. It does not contain doses or administration schedules.

All substances discussed in the article are of research nature and are not intended for human consumption. The description of their action is based solely on laboratory test results and experimental observations, not on clinical tests.

What are BPC-157 and TB-500

BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide – a chain of fifteen amino acids, the sequence of which was derived from a protein described in human gastric juice. Research on it has been conducted since the 1990s, primarily by a group from Zagreb, which has resulted in extensive preclinical literature covering models of healing of the digestive tract, tendons, ligaments, muscles and bones (Seiwerth et al., 2018, PMID 29998800).

TB-500 – what does this name actually mean

A correction is needed here because the repeated description is inaccurate. In materials about TB-500 you can read that it is “thymosin β4 composed of 44 amino acids”. Neither one nor the other corresponds to reality.

Human thymosin β4 is a protein composed of 43 amino acid residues. Preparations sold as TB-500, however, contain a short fragment of this molecule – in the analysis performed by liquid chromatography coupled with high-resolution mass spectrometry, the N-terminally acetylated 17-23 fragment of thymosin β4 with the sequence Ac-LKKTETQ was identified in TB-500, i.e. seven-amino acid peptide (Esposito et al., 2012, PMID 22962027).

This distinction is of practical importance. The Ac-LKKTETQ fragment includes the actin-binding region but is not identical to the full protein in either mass or the range of functions described for thymosin β4. Transferring all observations about the full molecule to the seven-amino-acid fragment is a simplification – and therefore we describe them separately in what follows. The identity of a specific material is determined solely by the sequence and weight confirmed in the batch analysis certificate.

Thymosin β4 – mechanism

Thymosin β4 is a small, abundant intracellular protein whose primary function is in the actin cytoskeleton. It functions as a protein that sequesters monomeric actin (G-actin), keeping its pool available for polymerization. Because the dynamic reconstruction of the cytoskeleton determines the cell’s ability to change shape and move, this protein participates in processes requiring cell migration – and these are an inherent element of tissue repair.

The described research directions for thymosin β4 include three related topics:

  • Cell migration and cytoskeleton remodeling – basic mechanism resulting directly from the actin sequestration function.
  • Angiogenesis – the formation of new vessels, which determines the supply of oxygen and substrates to the area covered by the repair.
  • Cell survival under conditions of injury. A study published in Nature described the activation of integrin-related kinase (ILK) and the effect on cell migration and survival in a cardiac repair model (Bock-Marquette et al., 2004, PMID 15565145). This topic was later summarized in a review (Shrivastava et al., 2010, PMID 20536454), and a more recent review discusses regenerative directions for this protein along with their limitations (Bock-Marquette et al., 2023, PMID 36709593).

Disclaimer that must accompany this section: the above observations apply to thymosin β4 as a complete protein studied in cell and animal models. These are not data about the seven-amino acid fragment present in TB-500 preparations, nor are they clinical data. The described model of heart repair does not constitute a basis for claims about the treatment of cardiovascular diseases in humans – such studies have not been conducted.

Data from animal models

All observations described in this section are derived from animal studies. There are no studies on humans confirming these observations. We mention them because they constitute a real body of literature – not because they allow us to predict anything in humans.

BPC-157 – healing models

Evidence gap scale

A systematic review of the use of BPC-157 in sports medicine published in 2025 summarizes the situation clearly: despite two decades of preclinical publications, there is a lack of randomized clinical trials to assess the effectiveness and safety profile in humans (Vasireddi et al., 2025, PMID 40756949). A 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries places this group among materials with an unconfirmed effectiveness profile (Mendias and Awan, 2026, PMID 41966639).

Practical consequence: there is no established safety profile for any of these compounds in humans. The claim that “peptides are safe and have no side effects” is not supported by the data – the lack of reported events where no one systematically records them is not evidence of safety.

BPC-157 and TB-500 – similarities and differences

Feature BPC-157 TB-500
Construction pentadecapeptide (15 amino acids) fragment 17-23 of thymosin β4 (Ac-LKKTETQ, 7 amino acids)
Sequence origin gastric juice protein Thymosin β4 actin-binding region
Main mechanism described angiogenesis, VEGF-related pathways actin sequestration, cell migration
Evidence status extensive preclinical literature, no RCTs the data mainly refer to the whole protein, not the fragment
DEFECT Category S0 – unapproved substances S2 – growth factors and related substances

The last line is sometimes omitted, but it is important: although both compounds are described in the same regenerative context, they belong to two different categories of the Prohibited List. This is due to the different nature of the particles, not a difference in risk assessment.

Regulatory status and anti-doping notice

None of the compounds discussed are medicinal products, dietary supplements or foodstuffs. They are not approved for trading in any jurisdiction.

BPC-157 – Category S0 (unapproved substances). It is listed by name on the WADA Prohibited List effective 2022 and is prohibited at all times. Category S0 includes substances that have not been approved by any regulatory authority for human use. We discuss it in more detail in the material about BPC-157 capsules. The KPV tripeptide, sometimes combined with BPC-157 in capsules, has its own article on the mechanism and research of KPV.

TB-500 / Thymosin β4 – Category S2 (peptide hormones, growth factors, related substances and mimetics), also prohibited at all times. Methods for detecting TB-500 in biological material have been developed and described in the analytical literature (Ho et al., 2012, PMID 23084823), and control strategies for thymosin β4 have also been developed in a population context (Delcourt et al., 2025, PMID 39314109). Detectability is therefore not an open question.

Since none of these compounds are registered medicines, there is no path to obtain a therapeutic use exemption (TUE). Anti-doping regulations are not limited to professionals: in Poland, the Prohibited List is in force through the Polish Anti-Doping Agency (POLADA), and amateur competitors taking part in competitions covered by these regulations are also subject to control. The current status should be verified each time in the applicable version of the Prohibited List.

Harm reduction

  • No safety profile in humans. Applies to both compounds. This is not a “favorable” profile – it simply has not been established because adequate research has not been done.
  • The identity of the material is sometimes ambiguous. The trade name “TB-500” does not indicate what is inside the package – full protein or fragment. The sequence and weight in the batch analysis certificate are decisive.
  • The post-traumatic context requires diagnostics. An injury to the musculoskeletal system requires diagnosis and treatment determined by a specialist. Research material is not an element of such proceedings and does not replace it.
  • For athletes – double risk. Both compounds are prohibited at all times, in two different categories, with no therapeutic exemption possible.

Frequently asked questions

Is TB-500 thymosin β4?

Not in the full sense. Human thymosin β4 is a protein composed of 43 amino acid residues, while the N-terminally acetylated fragment 17-23 of this molecule with the sequence Ac-LKKTETQ – a seven-amino acid peptide (PMID 22962027) was identified in the TB-500 preparations. Observations on the full protein do not automatically transfer to the fragment.

Are there clinical trials of BPC-157 or TB-500 in humans?

No. A 2025 systematic review indicates a lack of randomized clinical trials for BPC-157 (PMID 40756949). The situation is analogous for TB-500 – the available data concern animal and cell models, largely for the whole protein.

Do these peptides treat heart disease?

No. A study published inNaturedescribed the effects of thymosin β4 on cell migration and survival in an animal cardiac repair model (PMID 15565145). The animal model is not the basis for claims about the treatment of diseases in humans – no clinical trials have been conducted for this indication.

Are both compounds banned in sports?

Yes, both at all times, but in different categories: BPC-157 in S0 (unapproved substances, listed by name from 2022), and TB-500 and thymosin β4 in S2 (growth factors). It is not possible to obtain a therapeutic exemption for any of them.

Why does the article not provide doses or administration sites?

Because the substances in question do not have the status of medicinal products and have not undergone the registration process, which determines the dosage and route of administration. The values in circulation do not come from registration tests.

Summary

BPC-157 is a synthetic pentadecapeptide with extensive preclinical literature in bone, tendon and connective tissue healing models reporting effects on angiogenesis and VEGF-related pathways. TB-500, however, requires correction of the common description: it is not full thymosin β4, but the N-terminally acetylated fragment 17-23 of this protein (Ac-LKKTETQ), i.e. a seven-amino acid peptide – while the full molecule has 43 residues. The thymosin β4 mechanism involves actin sequestration, cell migration and angiogenesis, and studies describing it have been conducted on the whole protein in animal and cellular models. For both compounds, there is a lack of randomized clinical trials in humans, as confirmed by a 2025 systematic review – and therefore there is no established safety profile. Both are prohibited at all times on the WADA Prohibited List, in two different categories: BPC-157 in S0, and TB-500 in S2, with no therapeutic exemption possible.

Product documentation

Product pages for research materials, together with batch analytical documentation are available in the peptides for regeneration and peptides for injuries categories. Materials intended for research use only.

The principles of handling lyophilised material are discussed separately in our guide to selecting a solvent for reconstitution.

Bibliography

  1. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. PMID: 22962027
  2. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID: 40756949
  3. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29998800
  4. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654
  5. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-1125. PMID: 23782145
  6. Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl 7:191-196. PMID: 20388964
  7. Sebečić B, Nikolić V, Sikirić P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits. Bone. 1999;24(3):195-202. PMID: 10071911
  8. Stareśinić M, Sebečić B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208
  9. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145
  10. Shrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci. 2010;1194:87-96. PMID: 20536454
  11. Bock-Marquette I, Maar K, Maar S, et al. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. Int Immunopharmacol. 2023;116:109741. PMID: 36709593
  12. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta(4), in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID: 23084823
  13. Delcourt V, Garcia P, Chabot B, et al. Equine Doping Controls of Thymosin β4: A Population Study and Strategy for Misuse Detection. Drug Test Anal. 2025;17(7):1071-1077. PMID: 39314109
  14. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID: 41966639